Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Provided By PR Newswire
Last update: Jun 25, 2025
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience --
Read more at prnewswire.comNASDAQ:QTTB (10/21/2025, 10:10:03 AM)
3.26
-0.07 (-2.1%)
Find more stocks in the Stock Screener
QTTB Latest News and Analysis
